Literature DB >> 19099101

Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis.

Eliana Peresi1, Sônia Maria Usó Ruiz Silva, Sueli Aparecida Calvi, Jussara Marcondes-Machado.   

Abstract

OBJECTIVE: To evaluate the pattern of pro-inflammatory cytokines, anti-inflammatory cytokines and the acute phase response (APR) as markers of the response to treatment of pulmonary tuberculosis.
METHODS: Twenty-eight patients with pulmonary tuberculosis were evaluated at three time points: pretreatment (T0), treatment month 3 (T3) and treatment month 6 (T6). Levels of interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukine-10 (IL-10) and transforming growth factor-beta (TGF-beta) were determined using ELISA in the supernatant of peripheral blood mononuclear cell and monocyte culture. Levels of total protein, albumin, globulins, C-reactive protein (CRP), alpha-1-acid glycoprotein (AAG) and erythrocyte sedimentation rate (ESR) were also determined. All of these parameters were also evaluated, only once, in a group of healthy controls.
RESULTS: In relation to controls, patients presented cytokine levels and APR that were higher at T0, lower at T3 and either lower (TNF-alpha, IL-10, TGF-beta, AAG and ESR) or normal (IFN-gamma and CRP) at T6.
CONCLUSIONS: For individuals with negative smear sputum microscopy, CRP, AAG and ESR are potential markers of pulmonary tuberculosis and of the need for treatment; CRP (T0 > T3 > T6 = reference) can also be a marker of treatment response. In the patients, the Th0 profile (IFN-gamma, IL-10, TNF-alpha and TGF-beta), inducer of and protector against inflammation, predominated at T0, whereas the Th2 profile (IL-10, TNF-alpha and TGF-beta), protecting against the harmful pro-inflammatory effect of the remaining TNF-alpha, predominated at T6. The behavior of IFN-gamma (T0 > T3 > T6 = controls) suggests its use as a marker of treatment response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19099101     DOI: 10.1590/s1806-37132008001100009

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  18 in total

1.  Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.

Authors:  Elin M Svensson; Kelly E Dooley; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

2.  Assessment of Hematological Parameters in Pulmonary Tuberculosis Patients.

Authors:  K Rohini; M Surekha Bhat; P S Srikumar; A Mahesh Kumar
Journal:  Indian J Clin Biochem       Date:  2015-11-17

3.  Anemia in hospitalized patients with pulmonary tuberculosis.

Authors:  Marina Gribel Oliveira; Karina Neves Delogo; Hedi Marinho de Melo Gomes de Oliveira; Antonio Ruffino-Netto; Afranio Lineu Kritski; Martha Maria Oliveira
Journal:  J Bras Pneumol       Date:  2014 Jul-Aug       Impact factor: 2.624

4.  Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.

Authors:  Elin M Svensson; Francesca Aweeka; Jeong-Gun Park; Florence Marzan; Kelly E Dooley; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

5.  Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response.

Authors:  Karen Cilliers; Angela Menezes; Tariq Webber; Hazel M Dockrell; Jacqueline M Cliff; Léanie Kleynhans; Novel N Chegou; Nelita du Plessis; André G Loxton; Martin Kidd; Joel Fleury Djoba Siawaya; Katharina Ronacher; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2021-04-10       Impact factor: 3.131

6.  Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis.

Authors:  David T Mzinza; Derek J Sloan; Kondwani C Jambo; Doris Shani; Mercy Kamdolozi; Katalin A Wilkinson; Robert J Wilkinson; Geraint R Davies; Robert S Heyderman; Henry C Mwandumba
Journal:  Tuberculosis (Edinb)       Date:  2015-05-28       Impact factor: 3.131

7.  Distinctive biochemical changes in pulmonary tuberculosis and pneumonia.

Authors:  Füsun Sahin; Pınar Yıldız
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

8.  Analysis of Toll-like receptors, iNOS and cytokine profiles in patients with pulmonary tuberculosis during anti-tuberculosis treatment.

Authors:  Larissa Ragozo Cardoso de Oliveira; Eliana Peresi; Marjorie de Assis Golim; Mariana Gatto; João Pessoa Araújo Junior; Erika Alessandra Pellison Nunes da Costa; Jairo Aparecido Ayres; Maria Rita Parise Fortes; Sueli Aparecida Calvi
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

9.  Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease.

Authors:  Richard O Phillips; Fred S Sarfo; Jordi Landier; Reid Oldenburg; Michael Frimpong; Mark Wansbrough-Jones; Kabiru Abass; William Thompson; Mark Forson; Arnaud Fontanet; Fatoumata Niang; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10

10.  Inflammatory and immunogenetic markers in correlation with pulmonary tuberculosis.

Authors:  Beatriz Lima Alezio Muller; Daniela Maria de Paula Ramalho; Paula Fernanda Gonçalves dos Santos; Eliene Denites Duarte Mesquita; Afranio Lineu Kritski; Martha Maria Oliveira
Journal:  J Bras Pneumol       Date:  2013 Nov-Dec       Impact factor: 2.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.